425: BioNTech Launches CureVac Acquisition Bid, Reports Losses

BioNTech SE initiates an exchange offer to acquire all issued ordinary shares of CureVac N.V., aiming to expand its mRNA and oncology capabilities, while reporting significant net losses for recent periods and projecting a net loss for 2025.

Summary

• BioNTech SE has commenced an offer to acquire all issued ordinary shares of CureVac N.V. (Nasdaq: CVAC) in an all-stock transaction.
• For each tendered CureVac Share, BioNTech offers a number of newly registered American Depositary Shares (ADSs) determined by an Exchange Ratio, which is $5.4641 divided by the BioNTech ADS Volume-Weighted Average Price (VWAP).
• The Exchange Ratio is subject to a collar adjustment: if BioNTech ADS VWAP is >= $126.55, the ratio is 0.04318; if <= $84.37, the ratio is 0.06476.
• The offer commences on October 21, 2025, and is initially open until December 3, 2025.
• CureVac shareholders representing approximately 57% of shares, including dievini Hopp BioTech holding GmbH & Co. KG, KfW, Glaxo Group Limited, and CureVac's boards, have agreed to tender their shares.
• BioNTech reported a net loss of 802.4 million euros for the six months ended June 30, 2025, compared to a net loss of 1,122.9 million euros for the same period in 2024.
• Full-year 2024 saw a net loss of 665.3 million euros, a significant decline from a net profit of 930.3 million euros in 2023.
• Research and development expenses decreased by 5% to 1,034.7 million euros for the six months ended June 30, 2025, driven by reprioritization of clinical trials.
• BioNTech expects to incur a net loss for the full financial year 2025.
• The acquisition of CureVac is expected to provide significant strategic benefits, including complementary capabilities in target discovery, production, mRNA design, and delivery formulations, expanding BioNTech's pan-tumor oncology platform.
• BioNTech recently settled patent litigation with NIH for $791.5 million and with UPenn for up to $467.0 million, with Pfizer agreeing to reimburse BioNTech for $534.5 million of these claimed royalties.
• A global co-development and co-commercialization agreement with Bristol Myers Squibb (BMS) for BNT327 includes a $1.5 billion upfront payment and $2 billion in non-contingent anniversary payments through 2028, plus up to $7.6 billion in additional milestones.

Sentiment

Score: 4

Explanation: The filing presents a mixed outlook. While strategic acquisitions (CureVac, Biotheus) and significant collaboration deals (BMS) are positive for long-term pipeline and capabilities, the company is currently experiencing substantial net losses and projects continued losses for 2025. Declining COVID-19 vaccine demand and ongoing, complex patent litigation also weigh on the immediate financial performance and introduce considerable uncertainty.

Positives

• The acquisition of CureVac is expected to significantly expand BioNTech's capabilities in mRNA research, development, manufacturing, and commercialization, particularly in oncology.
• The transaction complements BioNTech's strategy by adding proprietary technologies in target discovery, production, mRNA design, and delivery formulations.
• A global co-development and co-commercialization agreement with Bristol Myers Squibb (BMS) for BNT327 includes a substantial upfront payment of $1.5 billion and $2 billion in non-contingent anniversary payments through 2028, with potential for up to $7.6 billion in additional milestones.
• BioNTech maintains a strong balance sheet with approximately 16.0 billion euros in total cash, cash equivalents, and security investments as of June 30, 2025.
• Successful settlement of patent litigation with NIH ($791.5 million) and UPenn (up to $467.0 million), with Pfizer reimbursing $534.5 million of claimed royalties.
• The company is advancing a diversified oncology pipeline with 16 clinical programs and six infectious disease programs, aiming for its first oncology launch as early as 2026.
• BioNTech continues to hold market leadership in COVID-19 vaccine in multiple key geographies, distributing approximately 180 million doses in 2024.
• Expansion of strategic partnership with CEPI to establish RNA vaccine manufacturing capabilities in Kigali, Rwanda, with up to $145 million in funding.
• Near-term science-based emission reduction targets (42% for Scope 1 & 2 by 2030) validated by SBTi, demonstrating commitment to ESG.

Negatives

• BioNTech reported a net loss of 802.4 million euros for the six months ended June 30, 2025, and a net loss of 665.3 million euros for the full year 2024.
• Operating loss for the six months ended June 30, 2025, was 1,035.2 million euros, following a 1,314.3 million euro operating loss in 2024.
• Demand for the COVID-19 vaccine is expected to continue decreasing, impacting future revenues, which currently depend heavily on Comirnaty sales.
• Uncertainty in COVID-19 vaccine demand and supply difficulties have led to significant inventory write-downs and contract manufacturing order cancellations in the past.
• CureVac shareholders who do not tender their shares in the offer may be subject to Dutch dividend withholding tax on the cancellation consideration, potentially resulting in a lower after-tax return.
• The MPox vaccine program (BNT165) is currently on clinical hold by the FDA, requiring BioNTech to address requests and assess next steps.
• The acquisition of CureVac will result in dilution for existing BioNTech shareholders, with former CureVac shareholders owning between approximately 4% and 6% of BioNTech's outstanding shares.
• BioNTech expects to incur substantial expenses related to the CureVac acquisition and integration, which could exceed anticipated savings in the near term.
• The company expects to incur a net loss for the full financial year 2025.

Risks

• Demand for the COVID-19 vaccine is expected to continue decreasing, impacting revenues heavily reliant on its sales.
• Uncertainty in COVID-19 vaccine demand and difficulties in targeting appropriate supply may lead to significant inventory write-downs and cancellations of contract manufacturing orders.
• Successful commercialization of product candidates depends on obtaining and maintaining adequate coverage and reimbursement levels from governmental authorities and third-party payors.
• Inability to increase marketing and sales capabilities independently or through third parties may hinder effective commercialization of product candidates.
• Operating results may fluctuate significantly, making future results difficult to predict, and falling below expectations could cause ADS price decline.
• Difficulties in developing and expanding the company, including managing acquisitions and growth, could disrupt operations.
• Business is dependent on successful development, regulatory approval, and commercialization of product candidates based on novel technology platforms, which is a lengthy, expensive, and uncertain process.
• Clinical trials may be delayed, more costly than anticipated, or face patient recruitment difficulties, materially impacting funding and business.
• Reliance on information technology systems exposes the company to security breaches, data loss, and other disruptions, compromising sensitive information and leading to liability.
• Novel technologies for COVID-19 vaccine and product candidates may be complex and difficult to manufacture, leading to difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping.
• Inadequate intellectual property protection or inability to enforce IP rights could hinder competitive effectiveness.
• Regulatory authorities may disagree with regulatory plans, leading to failure or delays in obtaining product approval.
• Approved products are subject to continuing regulatory oversight and ongoing obligations, with potential penalties for non-compliance or unanticipated problems.
• Safety issues discovered post-approval could negatively affect commercialization, lead to product withdrawal, or result in product liability claims.
• Government policies (e.g., export controls, tariffs) and negative public perception regarding vaccines and mRNA-based therapeutics could severely impact manufacturing and sales.
• Significant competition from other vaccine makers and pharmaceutical companies may lead to loss of market share.
• COVID-19 vaccine and product candidates are sensitive to temperature, shipping, and storage conditions, risking loss or damage.
• Failure to effectively compete in rapidly changing technological and scientific environments could prevent significant market penetration.
• Market opportunities for some product candidates may be small due to rare diseases or limited patient populations, hindering profitability.
• Achieving or maintaining profitability depends on penetrating global markets, subject to additional regulatory burdens and international operational risks.
• Even with regulatory approval, products may not gain market acceptance among medical communities and payors.
• Coverage and reimbursement may be limited or unavailable, making profitable sales difficult.
• Healthcare reform legislation and changes to the regulatory environment may increase difficulty and cost of obtaining approval and commercializing products.
• Drug marketing and reimbursement regulations in the EU and elsewhere may materially affect market access and coverage.
• Amount and ability to use net operating losses and R&D credits may be limited, and tax audits or changes in tax law could lead to additional liabilities.
• Obligation to withhold wage tax and social security contributions for contract service providers in Germany, with late payments subject to penalties.
• Substantial additional financing may be required, and failure to obtain it could delay, limit, reduce, or terminate product development or commercialization.
• International trade obligations (customs value, tariff classification) expose the company to penalties for non-compliance.
• As a foreign private issuer, BioNTech is exempt from certain U.S. securities and Nasdaq rules, limiting information available to ADS holders and potentially making ADSs less attractive.
• Insurance policies are expensive and may not cover all business risks, leaving the company exposed to significant uninsured liabilities.
• Adverse developments affecting financial institutions could impact operations and liquidity.
• Integration difficulties and failure to realize anticipated synergies from the CureVac acquisition.
• Inability to retain key CureVac Group employees post-acquisition.
• Counterparties to CureVac agreements may exercise contractual rights (e.g., termination) due to the acquisition.
• Substantial expenses related to the CureVac acquisition and integration may exceed expected savings.
• Value of Offer ADSs may not fully reflect market value due to collar adjustment.
• CureVac shareholders will be diluted in ownership in BioNTech post-acquisition.
• Shareholder litigation against BioNTech and CureVac could prevent or delay transactions, or result in damages.
• Share capital increases for the offer may result in extended settlement, with no interest for tendering CureVac shareholders.
• Volatility in BioNTech ADS market price due to various factors, including clinical data, regulatory news, and market conditions.
• Acquisitions, joint ventures, and collaborations may increase capital requirements, dilute shareholders, incur debt, or assume contingent liabilities, and may not realize expected benefits.
• BioNTech's articles of association designate specific U.S. courts as exclusive forum for certain litigation, potentially limiting shareholders' ability to obtain a favorable judicial forum.
• Holders of BioNTech ADSs may not participate in future preemptive subscription rights issues or elect to receive dividends in shares, leading to dilution.
• Principal shareholders and management own a significant percentage of ordinary shares, exerting significant control.
• Large number of shares eligible for sale could cause ADS price to drop.
• Acquisition of substantial interest by non-EU/non-EFTA investors requires German government approval, potentially restricting investments and limiting demand for ADSs.

Future Outlook

BioNTech aims to develop an innovative immunotherapy pipeline in oncology targeting multiple product approvals in the coming years and build a sustainable respiratory infectious disease vaccine business. The company plans to significantly invest in broad clinical evaluation of therapeutic approaches with pan-tumor potential and their commercialization. BioNTech expects to incur a net loss for the financial year 2025, with revenues projected between 1.7 billion and 2.2 billion euros, R&D expenses between 2.6 billion and 2.8 billion euros, and sales, general and administrative expenses between 650.0 million and 750.0 million euros. The company is preparing for global commercial roll-out of a new variant-adapted COVID-19 vaccine and intends to expand its R&D activities in the UK with a 1 billion euro investment over ten years, supported by a 129 million euro grant from the UK Government.

Management Comments

• Our boards believe that the acquisition of CureVac will have significant potential strategic benefits, including supporting the global execution of BioNTech's strategy to develop, manufacture, and commercialize mRNA-based medicines in oncology.
• The acquisition is expected to expand BioNTech's capabilities to research, develop, manufacture, and commercialize mRNA-based medicines as a pan-tumor technology platform in oncology.
• We believe our multi-technology combination of platforms and product candidates positions us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases.
• We are committed to translating science into survival for patients by advancing BioNTech's strategy and executing it to become a global immunotherapy powerhouse with multiple approved products and revenue streams.
• We aim to further advance our oncology pipeline with the aim of launching our first oncology product on the market as early as 2026 and establishing ourselves as an innovative oncology company with several approved products in various indications by 2030.

Industry Context

BioNTech operates in the intensely competitive and rapidly changing pharmaceutical market, particularly in the biotechnology and immunotherapy sectors. The global market for cancer immunotherapies was estimated at $12.2 billion in 2024 and is forecast to grow at a compound annual growth rate of 15% to around $31.3 billion by 2030, driven by increasing cancer prevalence, acceptance of immunotherapy, and R&D activities. BioNTech faces competition from large pharmaceutical and biotechnology companies like Sanofi, AstraZeneca, and Moderna, as well as academic institutions and smaller, early-stage companies. The company is leveraging its mRNA technology, which has proven effective with the COVID-19 vaccine, to address unmet medical needs in oncology and infectious diseases. The industry is also seeing increased regulatory scrutiny on AI systems and models, and evolving data privacy laws, which BioNTech is actively addressing.

Comparison to Industry Standards

• BioNTech's COVID-19 vaccine (Comirnaty) was the first-ever approved mRNA-based product and, to its knowledge, the fastest developed prophylactic vaccine from viral sampling to approval, demonstrating industry-leading speed in vaccine development.
• BioNTech maintains market leadership in COVID-19 vaccine in multiple key geographies (measured as more than 50% market-share), indicating strong competitive positioning against rivals like Moderna, Inc. and Novavax, Inc.
• The company's multi-technology approach, combining mRNA immunotherapies, protein-based therapeutics (e.g., bispecific antibodies, ADCs), and cell therapies, positions it as a pioneer in individualized, patient-centric therapeutic approaches, differentiating it from competitors focused on single modalities.
• BioNTech's investment in AI and machine learning, including the acquisition of InstaDeep, aims to accelerate drug discovery, development, and manufacturing, aligning with broader industry trends towards digital transformation in biotech.
• The company's commitment to equitable access to medicine, with over 30% of Comirnaty doses delivered to lowand middle-income countries in 2024, aligns with global health initiatives and potentially sets a standard for social responsibility in the pharmaceutical industry.
• The MPox vaccine program (BNT166) is supported through a partnership with CEPI to provide equitable access in lowand middle-income countries, reflecting a collaborative model for global health challenges.
• The collaboration with Bristol Myers Squibb for BNT327, a bispecific antibody, positions BioNTech in a competitive space for next-generation immuno-oncology treatments, with BNT327 showing encouraging clinical activity in PD-L1-low and -negative tumors, which are typically less responsive to current checkpoint inhibitors.

Management Changes

Corporate Governance

Legal Proceedings

• **CureVac Proceedings (Germany, UK, US):** CureVac has filed multiple lawsuits against BioNTech and Pfizer alleging infringement of European and U.S. patents related to Comirnaty. BioNTech has filed nullity and cancellation actions against CureVac's patents. Some German utility models were cancelled, and appeals are pending. UK High Court found EP565 invalid and EP949 valid and infringed, with appeals ongoing. US litigation was stayed pending inter partes review, where PTAB found Moderna's US patents unpatentable/invalid, which Moderna appealed.
• **Moderna Proceedings (Germany, UK, US, Netherlands, Ireland, Belgium):** Moderna has filed multiple patent infringement lawsuits against BioNTech and Pfizer regarding European patents EP949 and EP565, and U.S. patents 10,898,574, 10,702,600, and 10,933,127. In Germany, a first-instance decision found infringement of EP949, which BioNTech appealed. In the UK, EP565 was found invalid, and EP949 was found valid and infringed, with appeals ongoing. In the US, PTAB found Moderna's US patents unpatentable/invalid, which Moderna appealed. Proceedings are pending in the Netherlands, Ireland, and Belgium.
• **Arbutus and Genevant Proceedings (US):** Arbutus and Genevant filed a lawsuit against BioNTech and Pfizer alleging infringement of U.S. patents related to lipid nanoparticle technology used in Comirnaty. This proceeding is pending.
• **Other Genevant Proceedings (Arbitration):** Genevant initiated arbitration against BioNTech alleging breach of a license and co-development agreement related to practicing Genevant's technology outside prescribed fields of use and wrongful disclosure of confidential information. This proceeding is pending.
• **GlaxoSmithKline Proceedings (US, Ireland, Unified Patent Court, UK):** GSK filed multiple lawsuits against BioNTech and Pfizer alleging infringement of U.S. and European patents related to the cationic lipid used in Comirnaty. These proceedings are pending.
• **Promosome Proceedings (Unified Patent Court):** Promosome LLC filed a lawsuit against BioNTech and Pfizer alleging Comirnaty infringes EP 2 401 365. This proceeding is pending.
• **Ladewig Proceedings (US):** A securities class action complaint was filed against BioNTech and certain officers/directors alleging violations of the Exchange Act by overstating demand for Comirnaty and failing to adapt inventory. The complaint was dismissed by the Court on September 30, 2025, but plaintiffs have until October 30, 2025, to appeal.

Related Party Transactions

• ATHOS KG, through AT Impf GmbH, holds 42.1% of BioNTech's ordinary shares and is considered to have de facto control over the company.
• Medine GmbH, solely owned by Prof. Ugur Sahin, M.D. (CEO), holds 16.7% of BioNTech's shares.
• Transactions with entities controlled by ATHOS KG included purchases of various goods and services (0.2 million euros in 2024) and purchases of property and other assets (62.5 million euros in 2022).
• Key management personnel (Management Board and Supervisory Board members) received total compensation of 13.9 million euros in 2024 (8.9 million euros in 2023), including fixed compensation, short-term incentives, other variable compensation, and share-based payments.
• Prof. Ugur Sahin, M.D., exercised 4,374,963 options from his CEO Grant 2019 in August 2024, settled by delivery of treasury shares and cash for taxes.
• Jens Holstein received a one-time signing cash payment of 180,000 euros in 2023 and a special payment of 600,000 euros in 2023. Annemarie Hanekamp received a one-time signing bonus of 1,750,000 euros in 2024 (1,250,000 euros cash, 500,000 euros in shares).
• The member of the Supervisory Board Helmut Jeggle has held, and continues to hold functions and management positions at BioNTech's (indirect) controlling shareholders and/or their affiliates, constituting a potential conflict of interest.

Stakeholder Impact

• **Shareholders (CureVac):** Will receive BioNTech ADSs in exchange for their CureVac shares, leading to dilution in their ownership stake in the combined entity (4-6%). Non-tendering shareholders may face Dutch dividend withholding tax.
• **Shareholders (BioNTech):** Will experience dilution due to the issuance of new ADSs for the acquisition. The market price of BioNTech ADSs may fluctuate due to the acquisition, integration risks, and ongoing litigation.
• **Employees (CureVac):** BioNTech plans to comply with existing employment terms and benefits, but a strategic review post-acquisition may lead to changes in management composition and functions, and potential workforce adjustments in certain areas.
• **Employees (BioNTech):** Workforce optimization measures are planned, including potential reductions in Marburg and Idar-Oberstein, and consolidation across administrative functions and preclinical research in Europe and North America. However, overall headcount is expected to remain relatively stable over the next three years with new FTE positions created in other areas.
• **Customers:** The acquisition aims to expand BioNTech's capabilities in mRNA-based medicines, potentially leading to new and improved therapeutic options in oncology and infectious diseases.
• **Suppliers/Partners:** Existing agreements with CureVac counterparties may be affected by change-of-control clauses, potentially leading to renegotiations or terminations. BioNTech's reliance on single-source suppliers for critical components remains a risk.
• **Regulatory Bodies:** The acquisition and ongoing product development are subject to extensive regulatory oversight, including antitrust approvals and compliance with various health and safety laws. Legal proceedings with regulatory implications are ongoing.

Next Steps

• Complete the exchange offer for CureVac N.V. shares by December 3, 2025 (initial offer expiration), potentially followed by a subsequent offering period.
• Undertake a detailed strategic review of the CureVac business and formulate an integration plan post-acquisition.
• Continue to invest in research and development to advance the oncology pipeline, aiming for the first oncology product launch as early as 2026.
• Develop next-generation COVID-19 vaccines and COVID-19/influenza combination vaccines.
• Advance infectious disease programs, including vaccines for tuberculosis, malaria, and mpox.
• Address FDA requests and assess next steps for the BNT165 (Malaria Vaccine Program) clinical hold.
• Establish two new R&D centers and a UK headquarters in London, supported by a 129 million euro grant from the UK Government.
• Monitor and comply with evolving regulatory frameworks for AI systems and models in healthcare.

Key Dates

Recommendation

BioNTech is undergoing a significant strategic transformation through the acquisition of CureVac and substantial investments in its oncology pipeline, supported by a strong cash position and major collaboration deals like the one with BMS. These moves position the company for long-term growth in high-potential therapeutic areas. However, the company is currently reporting considerable net losses and expects this trend to continue in 2025, primarily due to declining COVID-19 vaccine demand and increased R&D expenses. The ongoing, complex patent litigation and integration risks associated with the CureVac acquisition introduce significant uncertainty. Given the long-term strategic potential balanced against current financial challenges and legal/operational risks, a 'hold' recommendation is appropriate for investors to monitor the execution of its strategy and the resolution of current headwinds before making further investment decisions.

Keywords

BioNTech, CureVac, Acquisition, mRNA, Oncology, Immunotherapy, COVID-19 Vaccine, SEC Filing, Exchange Offer, Biotechnology, Pharmaceuticals, Clinical Trials, Patent Litigation, Financial Results, BNT327, Comirnaty, Merger